ArticleJournal of hepatocellular carcinoma2026
Contrast-Enhanced CT Shell Features and Deep Learning for Predicting Early Transarterial Chemoembolization Refractoriness in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to develop and validate a predictive model for early refractoriness to transarterial chemoembolization (TACE)-termed early TACE refractoriness (ETR)-in patients with hepatocellular carcinoma (HCC). The model integrates contrast-enhanced CT (CECT) shell features (annular features at the tumor-liver parenchyma interface) with the Vision-Mamba (Vim) architecture, known for its efficiency in handling high-resolution medical images. Patients and Methods: This study was a two-center and retrospective study. Patients from center 1 were divided into the training set (n=254) and validation set (n=108), while patients from center 2 were used as the testing set (n=75). A joint model was constructed to predict ETR, and four Vim models without clinical features and 14 machine learning models based on clinical features were also developed for comparison. Model performance was evaluated by the accuracy, area under the curve (AUC), calibration curve, sensitivity, specificity, decision curve analysis (DCA) and Delong test. SHapley Additive exPlanations(SHAP) analysis were used to explain the predictions. Results: The combined model based on the Vim framework performs better than others. The AUC of the combined model in the training set, validation set and test set were 0.959, 0.956 and 0.942, respectively. The calibration curve and DCA verified the practicality of the combined model in clinical practice. SHAP provides a visual interpretation of the model. Conclusion: The Vim-based model integrating CECT and shell features shows promise for ETR prediction, offering a preliminary stratification tool. However, it remains a promising step rather than a definitive solution, requiring prospective validation due to the retrospective design and limited validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.